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Fra-1Osteosarcoma is the most common primary malignancy of bone and patients often develop pulmonary
metastases. Despite the advances in surgical and medical management, the mechanisms underlying human
osteosarcoma progression and metastasis remain to be elucidated. Gene expression proﬁles were compared
by the cDNA microarray technique between two different human osteosarcoma sublines, MNNG/HOS and
143B, which differ greatly in spontaneous pulmonary metastatic potential. Here we report an enhanced
expression of matrix metalloproteinase (MMP)-1 in the highly metastatic human osteosarcoma cell line 143B.
Moreover, the in vitro invasion activity of 143B cells was MMP-1-dependent. The activator protein (AP)-1
binding site in theMMP-1 gene promoter was required for the constitutive expression of MMP-1 in 143B cells.
Two AP-1 components, c-Jun and Fra-1, were phosphorylated, and bound to the AP-1 binding site of theMMP-
1 promoter in 143B cells. Activated c-Jun and Fra-1 were essential for MMP-1 gene expression in 143B cells.
Mitogen-activated protein kinase pathways including the c-Jun NH2-terminal kinase and the extracellular
signal-regulated kinase activate c-Jun and Fra-1 and thereby regulate c-Jun/Fra-1 mediated events, estab-
lishing the mitogen-activated protein kinase/AP-1/MMP-1 axis as important in 143B cells. These data suggest
that MMP-1 plays a central role in osteosarcoma invasion. Accordingly, MMP-1 might be a biomarker and
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Osteosarcoma is the most common primary malignancy of bone,
comprising 2.4% of all malignancies in pediatric patients and
approximately 20% of all bone cancers. The main incidence is during
the second decade of life and the tumors frequently localize to the
distal femur and proximal tibia [1,2]. The 5-year survival rate is
between 50 and 65% [3]. Current standard treatment is to use neo-
adjuvant chemotherapy followed by surgical resection. The cause of
death is usually due to pulmonary metastases since local disease canbe surgically treated [4,5]. Despite the advances in surgical and me-
dical management, the mechanisms underlying human osteosarcoma
progression and metastasis remain to be elucidated.
Cancer metastasis is a complex series of steps in which cancer cells
leave the original tumor site andmigrate to other parts of the body via the
bloodstream or the lymphatic system. Osteosarcoma metastasis is likely
regulated by multiple genes and results in the dissemination of tumor
cells from the primary site and eventual proliferation at the distant site
[6–8]. For example, neoplastic cell migration is driven by the C–X–C
chemokine receptor type 4 (CXCR4) and CXCR4's ligand, the stromal cell-
derived factor-1 (SDF-1), in osteosarcoma cells [9]. However, the
pathogenesis and metastasis of osteosarcomas is a complex cascade of
events that requires further understanding. Malignant cells break away
from the primary tumor and attach to and degrade proteins thatmake up
the surrounding extracellular matrix (ECM), which separates the tumor
fromadjoining tissue. By degrading these proteins, cancer cells are able to
breach the ECM and escape. In this process of neoplasm inﬁltration, there
is increasedproductionofmatrixmetalloproteinases (MMPs) fromtumor
cells [10]. Degradation of the ECM by MMPs is a crucial step in tumor
invasion andmetastasis [11]. In the setting of osteosarcoma,MMPs break
down extracellular collagens, facilitating both tumor and endothelial cell
invasion [12]. In addition to clearing apathway for invadingosteosarcoma
cells, MMPs are also capable of promoting angiogenesis [12].
Table 1
Enhanced gene expression in the high-frequent pulmonary metastatic 143B cells
compared to MNNG cells.




NM_002421 MMP1 Matrix metalloproteinase 1 134.9
NM_015714 G0S2 G0/G1 switch 2 66.9
NM_198560 LHFPL4 Lipoma HMGIC fusion partner-like 4 46.6
NM_033514 LIMS3 LIM and senescent cell antigen-like
domains 3
39.8
NM_145306 C10orf35 Chromosome 10 open reading frame 35 38.0
NM_000067 CA2 Carbonic anhydrase II 36.6
NM_015238 WWC1 WW and C2 domain containing 1 36.5
NM_001511 CXCL1 Chemokine (C–X–C motif) ligand 1 25.7
NM_172113 EYA2 Eyes absent homolog 2 (Drosophila) 24.9
NM_002867 RAB3B RAB3B, member RAS oncogene family 24.8
NM_014141 CNTNAP2 Contactin associated protein-like 2 24.1
NM_032531 KIRREL3 Kin of IRRE like 3 (Drosophila) 22.8
BM928667 BM928667 Homo sapiens cDNA clone IMAGE:5798808 22.6
NM_001017402 LAMB3 Laminin, beta 3 21.9
NM_002089 CXCL2 Chemokine (C–X–C motif) ligand 2 20.2
NM_000693 ALDH1A3 Aldehyde dehydrogenase 1 family,
member A3
20.1
NM_001037341 PDE4B Phosphodiesterase 4B, cAMP-speciﬁc
(phosphodiesterase E4 dunce homolog,
Drosophila)
20.0
NM_198389 PDPN Podoplanin 18.7
NM_198179 QRFPR Pyroglutamylated RFamide peptide
receptor
18.7
NM_000514 GDNF Glial cell derived neurotrophic factor 14.4
NM_004417 DUSP1 Dual speciﬁcity phosphatase 1 14.3
AK025855 CDH4 Cadherin 4, type 1, R-cadherin (retinal) 14.1
NM_013409 FST Follistatin 13.6
NM_006823 PKIA Protein kinase (cAMP-dependent,
catalytic) inhibitor alpha
13.2
NM_002521 NPPB Natriuretic peptide precursor B 13.2
NM_005559 LAMA1 Laminin, alpha 1 13.0
NM_001165 BIRC3 Baculoviral IAP repeat-containing 3 12.9
NM_001542 IGSF3 Immunoglobulin superfamily, member 3 12.8
NM_014859 RICH2 Rho-type GTPase-activating protein RICH2 12.5
NM_005167 PPM1J Protein phosphatase 1J (PP2C domain
containing)
12.4
NM_000076 CDKN1C Cyclin-dependent kinase inhibitor 1C
(p57, Kip2)
12.2
NM_001630 ANXA8L2 Annexin A8-like 2 11.9
NM_017413 APLN Apelin 11.9
NM_020645 NRIP3 Nuclear receptor interacting protein 3 11.9
NM_004994 MMP9 Matrix metalloproteinase 9 11.8
NM_002547 OPHN1 Oligophrenin 1 11.3
NM_000899 KITLG KIT ligand 11.3
NM_020134 DPYSL5 Dihydropyrimidinase-like 5 11.3
NM_153448 ESX1 ESX homeobox 1 11.0
NM_015278 SASH1 SAM and SH3 domain containing 1 10.9
BG821581 BG821581 Homo sapiens cDNA clone IMAGE:4864578 10.9
NM_003247 THBS2 Thrombospondin 2 10.7
NM_001147 ANGPT2 Angiopoietin 2 10.2
BC092429 BC092429 Homo sapiens cDNA clone
IMAGE:30530513
10.1
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three related osteosarcoma cell lines, namely TE85, MNNG/HOS and
143B, with varying tumor growth capabilities and spontaneous
metastatic potentials. These three osteosarcoma lines were derived
from the same patient [13], suggesting that they should have a similar
genetic background. TheMNNG/HOS cell line is a subclone derived from
TE85 that has been further transformed with N-methyl-N′-nitro-N-
nitrosoguanidine (MNNG), while the 143B cell line is a Ki-ras trans-
formed TE85 line [14,15]. In vitro characterization demonstrated that
143B cells exhibited the greatest cell motility/invasion potential and
anchorage independent growth ability among the three cell lines [16].
When these cells were orthotopically injected into the proximal tibia of
athymic nude mice, both MNNG/HOS and 143B cells were able to form
tumors with high efﬁciency, while TE85 cells were not able to form any
tumors. Furthermore, the 143B injected animals developed numerous
pulmonary metastases, while the MNNG/HOS injected animals only
occasionally produced pulmonary metastases. Thus, these human
osteosarcoma lines, MNNG/HOS and 143B, allow the investigation of
different stages of osteosarcoma invasion and pulmonary metastasis.
In this study, we analyzed osteosarcoma invasion and pulmonary
metastasis-related factors such as MMPs by using MNNG/HOS and
143B cells.
2. Materials and methods
2.1. Cell lines
The human osteosarcoma cell lines MNNG/HOS (MNNG) and 143B
were cultured in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal calf serum (FCS; Biological Industries, Kibbutz Beit
Haemek, Israel), 50 U/ml penicillin and 50 μg/ml streptomycin.
2.2. Reagents
Mousemonoclonal antibody toMMP-1was purchased fromDaiichi
Fine Chemical (Takaoka, Japan).Mousemonoclonal antibodies to actin
and retinoblastoma protein (Rb) were purchased from NeoMarkers
(Fremont, CA, USA). Rabbit polyclonal antibodies to phospho-c-Jun
(Ser73), phospho-Fos-related antigen (Fra)-1 (Ser265), c-Jun NH2-
terminal kinase (JNK), phospho-JNK (Thr183 and Tyr185), MKK4 and
phospho-MKK4 (Ser257 and Thr261), and rabbit monoclonal anti-
bodies to c-Jun, Fra-1, extracellular signal-regulated kinase (ERK)1/2
and phospho-ERK1/2 (Thr202 and Tyr204) were purchased from Cell
Signaling Technology (Beverly, MA, USA). JNK inhibitor SP600125 and
mitogen-activated protein kinase (MAPK)/ERK kinase1/2 inhibitor
PD98059 were obtained from Calbiochem (La Jolla, CA, USA).
2.3. RNA extraction and synthesis of Cy3- and Cy5-labeled cRNAs
Total cellular RNA was extracted using an RNeasy Plus mini kit
(Qiagen, Hilden, Germany). The Low RNA Fluorescent Linear Ampli-
ﬁcation kit (Agilent Technologies, Santa Clara, CA, USA) was used for
cDNA synthesis. To initiate the synthesis, 1.2 μl oligo(dT)-T7 primer
was added to 11.5 μl of a solution containing 500 ng total RNA from
cells and incubated at 65 °C for 10 min, chilled on ice and incubated for
5 min. Four microliters of 5× ﬁrst-strand buffer, 2 μl of 0.1 M DTT, 1 μl
of 10 mM dNTP mix, 0.5 μl of RNaseOUT (Agilent Technologies), and
1 μl of MMLV-reverse transcriptase were added to the RNA solution
and incubated at 40 °C in a circulating water bath for 2 h, and then
incubated at 65 °C for 15 min to inactivate MMLV-reverse trans-
criptase, chilled on ice and incubated for 5 min. The same kit was used
for antisense RNA ampliﬁcation by in vitro transcription using T7 RNA
polymerase. Twenty microliters of 4× transcription buffer, 8 μl of NTP
mix, 6 μl of 0.1 M DTT, 6.4 μl of 50% polyethylene glycol, 0.5 μl of
RNaseOUT, 0.6 μl of inorganic pyrophosphatase, 2.4 μl of either Cy3-
CTP (10 mM) or Cy5-CTP (10 mM), and 0.8 μl of T7 RNA polymerasewere added to the 20 μl of cDNA solution and incubated in a circulating
water bath at 40 °C for 2 h. In this study, RNA from MNNG cells was
labeled with Cy3, whereas 143B cell RNA was labeled with Cy5.
Labeled cRNA was puriﬁed with RNeasy mini spin columns (Qiagen).
2.4. Microarray experiments and data analysis
A Human1A ver2 Oligo Microarray kit (Agilent Technologies) was
used for microarray analysis. 0.75 μg of Cy3-labeled cRNA was mixed
with the same amount of Cy5-labeled cRNA and used for subsequent
hybridization. Ten microliters of 25× fragmentation buffer was added
to 240 μl of hybridization mixture consisting of 0.75 μg of labeled
cRNA and 50 μl of 10× blocking agent, and incubated at 60 °C for
30 min, and 200 μl of 2× hybridization buffer was added. The mixture
was hybridized to the slide and hybridization was carried out for 17 h
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Agilent Gene Expression washing buffer 1 (Agilent Technologies) for
1 min at room temperature. After another wash in Agilent Gene
Expressionwashing buffer 2 (Agilent Technologies) for 1 min at 37 °C,
the slide was dried. Slides were scanned using a Microarray scanner
(Agilent Technologies). Feature extraction and data normalization
were conducted with Agilent Feature Extraction software version
9.5.3.1. Spots that did not pass quality control procedures were
ﬂagged by the software and removed from the analysis following
manual check. The relative expression level was measured through
the normalized ratio of signal intensities of Cy5/Cy3 ﬂuorescence.2.5. Reverse transcription-PCR (RT-PCR)
Total cellular RNA from cells was extracted with Trizol (Invitrogen,
Carlsbad, CA, USA) according to the protocol provided by the manu-
facturer. First-strand cDNA was synthesized from 1 μg total cellular
RNA using a PrimeScript RT-PCR kit (Takara Bio Inc., Otsu, Japan) with
random primers. The sequences of the primers were described pre-
viously [17–19]. The primers used were 5′-GGTGCCCAGTGGTT-
GAAAAAT-3′ (forward) and 5′-CATCACTTCTCCCCGAATCGT-3′
(reverse) for MMP-1, 5′-AGCTGTTGGTGAAAAGGTGGTCTATG-3′ (for-
ward) and 5′-GCGCTTCTGGTGGCCCTTGGAGTGTG-3′ (reverse) for
CXCR4, and 5′-GCCAAGGTCATCCATGACAACTTTGG-3′ (forward) and
5′-GCCTGCTTCACCACCTTCTTGATGTC-3′ (reverse) for glyceraldehyde
3-phosphate dehydrogenase (GAPDH). The length of the semiquan-
titative RT-PCR for each gene was as follows: 30 cycles for MMP-1,
30 cycles for CXCR4, and 27 cycles for GAPDH. The PCR products wereFig. 1.MMP-1 is highly expressed in 143B cells. (A) Expression of MMP-1 and CXCR4mRNA i
(loading control). (B) Intracellular expression of MMP-1 protein in MNNG and 143B cel
immunoblotting with anti-MMP-1 antibody and anti-actin antibody, respectively. (C) MMP-
were seeded and then incubated for 24, 48 and 72 h. MMP-1 protein levels in the culture su
experiments in periods of 24, 48 or 72 h (**pb0.01). (D) Relative cellular proliferation of M
Proliferation of cultured cells was determined by WST-8 based colorimetric assay Cell Coun
microplate reader during a period of 0–24 h. The proliferation rates are expressed relative to
independent WST-8 experiments in a period of 24 h.fractionated on 2% agarose gels and visualized by ethidium bromide
staining.2.6. Western blot analysis
Cells were lysed in a buffer containing 62.5 mM Tris–HCl (pH 6.8),
2% sodium dodecyl sulfate, 10% glycerol, 6% 2-mercaptoethanol and
0.01% bromophenol blue. Equal amounts of protein (20 μg) were
subjected to electrophoresis on sodium dodecyl sulfate-polyacryl-
amide gels, followed by transfer to polyvinylidene diﬂuoride mem-
brane and sequential probing with speciﬁc antibodies. The bands
were visualized with an enhanced chemiluminescence kit (Amer-
sham Biosciences, Piscataway, NJ, USA).2.7. Transfection and luciferase assay
Wild type (WT) humanMMP-1 promoter−525/+15, deletion mu-
tants, including −300/+15, −91/+15 and −41/+15, and various
point mutants, including activator protein (AP)-1 mutant (−70/−68),
E-twenty six (ETS) mutant (−88/−85), ETS mutant (−48/−45) and
ETSdoublemutant (−88/−85,−48/−45),were cloned intopGL2-Basic
plasmid (Promega, Madison, WI, USA) [20,21]. MNNG and 143B cells
were transfected with the appropriate reporter plasmids using Lipo-
fectamine 2000 (Invitrogen). After 24 h, the cells were washed in
phosphate-buffered saline (PBS) and lysed in reporter lysis buffer
(Promega). Lysates were assayed for reporter gene activity with the
dual luciferase assay system (Promega). Luciferase activities werenMNNG and 143B cells. RT-PCR analysis was carried out for MMP-1, CXCR4 and GAPDH
ls. Western blot analysis for MMP-1 and actin (loading control) were performed by
1 proteins in the culture supernatants fromMNNG and 143B cells. MNNG and 143B cells
pernatants were determined by ELISA. Data are mean±SD of three independent ELISA
NNG and 143B cells. MNNG and 143B cells were seeded and then incubated for 24 h.
ting kit 8. Cell proliferation was determined by scanning absorbance at 450 nm with a
that of MNNG or 143B cells at 0 h, which was deﬁned as 1. Data are mean±SD of three
1546 R. Kimura et al. / Biochimica et Biophysica Acta 1813 (2011) 1543–1553normalized relative to the Renilla luciferase activity from cotransfected
phRL-TK.
2.8. Small interfering RNA (siRNA)
To repress MMP-1, c-Jun and Fra-1, predesigned double-stranded
siRNAs (ON-TARGET plus SMART pool; Dharmacon Inc., Lafayette, CO,
USA) were used. A siCONTROL non-targeting siRNA pool (Dharmacon
Inc.) was used as a negative control. All siRNA transfections were
performed using a MicroPorator MP-100 (Digital Bio Technology,
Seoul, Korea) according to the instructions supplied by the manufac-
turer for optimization and use.
2.9. Preparation of nuclear extracts and electrophoretic mobility shift
assay (EMSA)
Cell pelletswere swirled to a loose suspension and treatedwith lysis
buffer [0.2 ml, containing 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM
EDTA, 0.1 mMEGTA, 2 mMAEBSF and 1 mMDTT]with gentlemixing at
4 °C. After 10 min, NP40 was added to a ﬁnal concentration of 0.6% and
the solutionwas centrifuged immediately at 1,000 rpm for 5 min at 4 °C.
The supernatants were removed carefully and the nuclear pellets were
diluted immediately by the additionofNP40-free lysis buffer (1 ml). The
nuclei were then recovered by centrifugation at 1,000 rpm for 5 min at
4 °C. Finally, the remaining pellets were suspended on ice in extraction
buffer [20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA,
1 mMDTT, 2 mM AEBSF, 33 μg/ml aprotinin, 10 μg/ml leupeptin, 10 μg/
ml E-64 and 10 μg/ml pepstatin A] for 30 min to obtain the nuclearFig. 2. 143B cells markedly invade through type I collagen and Matrigel. (A) Real time cell in
MNNG and 143B cells were seeded in the upper chamber containing serum-free medium, an
FCS. Then, cells were incubated for 24 h. Cell invasion was monitored using RT-CES system. D
period of 24 h (right) (*pb0.05). (B) Real time cell invasion assay with Matrigel. The upper c
MNNG and 143B cells.fraction. All fractions were cleared by centrifugation for 15 min at
15,000 rpm. Transcription factors bound to speciﬁc DNA sequences
were examined by EMSA as described previously [22]. To examine the
speciﬁcity of the probe, we preincubated unlabeled competitor oli-
gonucleotides with nuclear extracts for 15 min before incubation with
probes. The probes or competitors usedwere prepared by annealing the
respective sense and antisense synthetic oligonucleotides of the
following DNA sequences: for the WT AP-1 element of the MMP-1
gene, 5′-GATCTTATAAAGCATGAGTCAGACACCTCT-3′; for the AP-1
element mutant of the MMP-1 gene, 5′-GATCTTATAAAGCATGAtggA-
GACACCTCT-3′ (sites of mutation are indicated in lowercase); for the
ETS element (−88/−85) of the MMP-1 gene, 5′-GATCGCTAATCAA-
GAGGATGTTATAAAGCA-3′; for the nuclear factor-κB (NF-κB) element
of the interleukin-2 receptor α chain (IL-2Rα) gene, 5′-GATCCGG-
CAGGGGAATCTCCCTCTC-3′; and for the AP-1 element of the IL-8 gene,
5′-GATCGTGATGACTCAGGTT-3′. The oligonucleotide 5′-GATCTGTC-
GAATGCAAATCACTAGAA-3′, containing the consensus sequence of the
octamer binding motif, was used to identify speciﬁc binding of the
transcription factor Oct-1. The underlined sequences above are the
NF-κB, AP-1, ETS and Oct-1 binding sites, respectively. To identify
transcription factors in the DNA–protein complex shown by EMSA, we
usedantibodies (SantaCruzBiotechnology, SantaCruz, CA, USA) speciﬁc
for various AP-1 family proteins (c-Fos, FosB, Fra-1, Fra-2, c-Jun, JunB
and JunD) and ETS family proteins [Ets-1, PU.1, polyomavirus enhancer-
A binding protein-3 (PEA3), ERM and ER81] to elicit a supershift DNA–
protein complex formation. These antibodies were incubated with the
nuclear extracts for 45 min at room temperature before incubationwith
radiolabeled probe.vasion assay with type I collagen. The upper chamber was coated with type I collagen.
d the lower chamber contained serum-free medium ormedium supplemented with 10%
ata are mean±SD of three independent invasion experiments for every 1 h (left) and a
hamber was coated with Matrigel. Cell invasion was monitored using RT-CES system for
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For cell invasion assay, ACEA electrosensing ×16 microtiter plates
were coated with Matrigel (BD Biosciences, San Jose, CA, USA) diluted
1:20 in starvation media or 215 μg/ml rat tail type I collagen (BD
Biosciences).MNNGor143Bcellswere seededat3×105 cells/ml in100 μl
of serum-freemedium in the upper chamberwith 8 μmpore size, and the
lower chamber contained serum-freemediumormedium supplemented
with 10% FCS. The ACEA plate was connected to the ACEA Device Station
at 37 °C, and the cells that invaded through Matrigel or type I collagen
were monitored every 1 h in real time by an ACEA Sensor Analyzer for
24 h and quantitated using ACEA RT-CES Integrated Software.2.11. MMP-1 enzyme-linked immunosorbent assay (ELISA) and cell viability
Cells were seeded at 5×104 cells/ml in 2 ml of medium sup-
plemented with 10% FCS in a 6-well culture plate and incubated for 24,
48or 72 h. The levels ofMMP-1protein in the culture supernatantswere
determined using a human MMP-1 ELISA kit (Abcam, Cambridge, UK).
Cells were seeded at 5×104 cells/ml in 100 μl of medium sup-
plemented with 10% FCS in a 96-well microculture plate and
incubated for 24 or 48 h. Cell viability was assessed using the water-
soluble tetrazolium (WST)-8 based colorimetric assay Cell Counting
kit 8 (Wako Pure Chemical Industries, Osaka, Japan). After 24 or 48 h
of culture, WST-8 (5 μl) was added for the last 4 h of incubation and
absorbance at 450 nm was measured using an automated microplate
reader. Measurement of mitochondrial dehydrogenase cleavage of
WST-8 to formazan dye provided an indication of cell viability. Viabi-
lity in untreated control cultures was scaled to represent 100%, and all
treated groups were compared with this value.2.12. Statistical analysis
Data were expressed as mean±standard deviation (SD). Differ-
ences between groupswere examined for statistical signiﬁcance using
the unpaired Student's t-test. P values less than 0.05 denoted the
presence of a statistically signiﬁcant difference.Fig. 3. 143B cells invade in an MMP-1-dependent manner. 143B cells were transfected
with either MMP-1 or control siRNA and then incubated for 24 h. (A) MMP-1 and actin
protein levels at 24 h after transfection were determined by Western blot analysis.
(B) The cells at 24 h after transfection were seeded and then incubated for another 24 h.
MMP-1 protein levels in the culture supernatants were determined by ELISA. Data are
mean±SD of three independent ELISA experiments in a period of 24 h (**pb0.01).
(C) The cells at 24 h after transfection were seeded and then incubated for another 24 h.
The viability of cultured cells was determined by WST-8 assay. Data are mean±SD of
three independent WST-8 experiments in a period of 24 h. (D) The cells at 24 h after
transfection were seeded in the type I collagen-coated upper chamber containing
serum-free medium, and the lower chamber contained medium supplemented with
10% FCS. Then cells were incubated for 24 h. Cell invasion was monitored using RT-CES
system. Data are mean±SD of three independent invasion experiments in a period of
24 h (*pb0.05).3. Results
3.1. MMP-1 is highly expressed in the high-frequent pulmonary metastatic
human osteosarcoma cell line 143B
We ﬁrst compared gene expression proﬁles by cDNA microarray
analysis between two different human osteosarcoma sublines, MNNG
and 143B, which differ greatly in spontaneous pulmonary metastatic
potential. In 143B cells, 44 genes were up-regulated more than ten-
fold compared to MNNG cells (Table 1). In particular, MMP-1,
otherwise known as collagenase-1, was up-regulated 134.9-fold and
the chemokine receptor CXCR4wasup-regulated 5.7-fold compared to
MNNG cells. CXCR4's ligand SDF-1α, a molecule endowedwith potent
chemotactic activity, was up-regulated less than two-fold in 143B cells
compared to MNNG cells.
We also analyzed the levels of speciﬁc mRNAs by RT-PCR. MMP-1
and CXCR4 were highly expressed in 143B cells (Fig. 1A). Intracellular
MMP-1 was robustly expressed in 143B cells and barely, if at all,
present in MNNG cells (Fig. 1B). Furthermore, we studied extracel-
lular protein levels of MMP-1. From 143B cells, 1,500-fold more
MMP-1 was released than from MNNG cells in a period of 24 h, and
even more so at 48 and 72 h (Fig. 1C). In contrast, there was no
difference in proliferation between MNNG and 143B cells in a period
of 24 h (Fig. 1D). These data demonstrate that MMP-1 is markedly
expressed in and released from 143B cells comparedwithMNNG cells.3.2. 143B cells markedly invade in an MMP-1-dependent manner
We next determined the ability of osteosarcoma cell lines to
invade through a type I collagen matrix, a substrate of MMP-1, in a
real time cell invasion assay. 143B cells markedly invaded in a serum-
and time-dependent manner, whereas MNNG cells were signiﬁcantly
less invasive (Fig. 2A). Similarly, 143B cells but not MNNG cells
potently invaded through Matrigel (Fig. 2B).
Next, we examined MMP-1-dependent invasion of 143B cells. To
this end, we treated 143B cells with MMP-1 siRNA that speciﬁcally
inhibited the intracellular expression (Fig. 3A) and extracellular
release (Fig. 3B) of MMP-1, while there was no difference in cellular
proliferation (Fig. 3C). Notably, MMP-1 knockdown caused a signif-
icant decrease in 143B cell invasion thorough type I collagen (Fig. 3D).
These data suggest that MMP-1 plays a central role in invasion of 143B
cells.
3.3. The AP-1 binding site in the MMP-1 gene promoter is required for
the constitutive expression of MMP-1 in 143B cells
Previous studies have shed some light on the possible transcrip-
tional regulatorymechanisms ofMMP-1 gene expression, suggesting a
crucial role of the 5′ ﬂanking sequence containing the oncogene
responsive unit composed of the AP-1 motif and the PEA3/ETS motif
[23]. We next wished to analyze the transcriptional regulation of the
MMP-1 gene promoter in 143B cells. Thus, we performed reporter
gene assays in MNNG and 143B cells using various MMP-1 promoter-
Fig. 4. AP-1 binding site is required for MMP-1 transactivation in 143B cells. Schematic diagrams of reporter constructs containing humanMMP-1 promoter cloned into pGL2-Basic
plasmid are shown (left). MNNG or 143B cells were transfected with the indicated MMP-1 reporter plasmids together with phRL-TK. Cells were harvested 24 h post-transfection and
luciferase activity was measured with a luminometer. Luciferase activities were normalized based on the Renilla luciferase activity from cotransfected phRL-TK. The activities are
expressed relative to that of 143B cells transfected with pGL2-Basic, which was deﬁned as 1 (right). Data are mean±SD of three independent transfection experiments. *pb0.05 vs.
the activity of 143B cells transfected with pGL2-MMP-1 (−525/+15).
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promoter −525/+15, which encompasses its AP-1 and two ETS
binding sites (Fig. 4, top), wasmore than four-fold higher in 143B cells
compared to MNNG cells (Fig. 4). In contrast, the activity of the
parental luciferase expression vector pGL2-Basic was not different
betweenMNNG and 143B cells. We next performed the reporter assay
in 143B cells using deletion mutants of the MMP-1 promoter. As long
as the AP-1 and ETS binding sites were retained, luciferase activityFig. 5. c-Jun/Fra-1 and PEA3 are bound to the AP-1 and ETS binding sites of theMMP-1 promo
in nuclear extracts derived from MNNG and 143B cells. Nuclear extracts from MNNG and
analysis for Rb (loading control) was performed by immunoblotting with anti-Rb antibody
sites of theMMP-1 promoter in 143B cells. Nuclear extracts from 143B cells were treated wit
binding site (−88/−85) probe derived from theMMP-1 gene in the absence or presence of t
type (WT) AP-1 site, an MMP-1 mutant AP-1 site, the MMP-1 WT ETS site (−88/−85), an
Arrowhead: the DNA binding complex supershifted by antibody.was unaffected by deleting upstream promoter sequences (Fig. 4), but
deletion of AP-1/ETS sites in theMMP-1 promoter−41/+15 severely
decreased transcription in 143B cells. We then utilized point mutants
of the MMP-1 promoter. Activities of MMP-1 promoter AP-1 mutant
(−70/−68) and ETS double mutant (−88/−85, −48/−45) were
signiﬁcantly decreased, whereas mutation at the ETS site (−48/−45)
slightly decreased the promoter activity (Fig. 4). The promoter activity
tended to be also lower in ETS mutant (−88/−85), albeit this waster in 143B cells. (A) EMSA with the AP-1 and ETS binding sites of theMMP-1 promoter
143B cells were incubated with the indicated probes (top and middle). Western blot
(bottom). (B) Supershift assay and competition analysis with the AP-1 and ETS binding
h antibodies against the indicated transcription factors and incubated with AP-1 or ETS
he indicated unlabeled double-stranded oligonucleotides representing the MMP-1 wild
AP-1 site from the IL-8 promoter or a consensus NF-κB site from the IL-2Rα promoter.
Fig. 6. Activation of c-Jun and Fra-1 in 143B cells. Western blot analysis of MNNG and 143B cell extracts was performed using the indicated antibodies.
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and ETS binding sites in the MMP-1 promoter are required for the
constitutive expression of MMP-1 in 143B cells.
In the next step, we determined the transcription factors binding to
the AP-1 and ETS (−88/−85) elements in theMMP-1 promoter. EMSA
was performed with double-stranded oligonucleotides representing
the AP-1 and ETS (−88/−85) elements. Protein complexes bound to the
AP-1 and ETS (−88/−85) sites were more strongly detected with
nuclear extracts derived from 143B cells compared to MNNG cells
(Fig. 5A). As a control, no difference in Rb expression was noted in
nuclear extracts from MNNG and 143B cells. The speciﬁcity of DNA–
protein complex formation was assessed by competition studies with
unlabeled competitors. As expected, a “cold” MMP-1 WT AP-1 double-
stranded oligonucleotide or an AP-1 site from the IL-8 promoter ef-Fig. 7. Inhibitors of JNK and ERK suppress MMP-1 expression. 143B cells were treated with
analyses from 143B cells treated with SP600125 (A) or PD98059 (B) were performed by imm
cells treated with SP600125 or PD98059 was performed with the indicated probes.fectively competed with the labeled MMP-1 AP-1 probe and eliminated
binding of nuclear extracts from143B cells (Fig. 5B, top, lanes 2 and 4). In
contrast, the unlabeled MMP-1 AP-1 mutant or consensus NF-κB site
from the IL-2Rα promoter could not compete with the labeled AP-1
probe (Fig. 5B, top, lanes 3 and 5). Moreover, the unlabeled MMP-1 ETS
site but not NF-κB site from the IL-2Rα promoter competed with the
labeled MMP-1 ETS probe (Fig. 5B, bottom, lanes 2 and 3). The exact
composition of the transcription factor DNA–protein complexes in 143B
cells was analyzed by supershift assay utilizing speciﬁc antibodies
(Fig. 5B, lanes 6–12 on top and lanes 4–8 on bottom). These experiments
revealed that c-Jun and Fra-1 were the predominant components of the
AP-1 complexes on theMMP-1 AP-1 site in 143B cells (Fig. 5B, top, lanes
8 and 10). The antibody against PEA3 also induced supershifted com-
plexes in 143B cells using the ETS (−88/−85) site of MMP-1 gene as aSP600125 (0, 2.5, 5 or 10 μM) or PD98059 (0, 2.5, 5 or 10 μM) for 48 h. Western blot
unoblotting with the indicated antibodies. (C) EMSA with nuclear extracts from 143B
1550 R. Kimura et al. / Biochimica et Biophysica Acta 1813 (2011) 1543–1553probe (Fig. 5B, bottom, lane 6). These data suggest that c-Jun/Fra-1 and
PEA3 are bound to theAP-1 andETSbinding sites of theMMP-1promoter
in 143B cells, respectively.
3.4. Phosphorylated c-Jun and Fra-1 are essential for MMP-1 gene
expression in 143B cells
We next performed Western blot analysis for phosphorylated
proteins in MNNG and 143B cells (Fig. 6). Transcription factor c-Jun
and upstream activators of c-Jun, JNK and MKK4, were markedly
phosphorylated in 143B cells compared to in MNNG cells. In 143B
cells, Fra-1 was signiﬁcantly expressed as compared to MNNG cells.
Fra-1 was also highly phosphorylated in 143B cells. However, the
upstream activator of Fra-1, ERK1/2, was phosphorylated at the same
levels in both cell lines.
To further investigate the role of c-Jun and Fra-1 in MMP-1 ex-
pression, we used SP600125, an inhibitor of JNK1/2, and PD98059, an
inhibitor of MAPK/ERK kinase1/2 that is an upstream activator of
ERK1/2. In 143B cells, treatment with SP600125 inhibited the phos-
phorylation of c-Jun and its upstream activator, JNK, in a dose-
dependentmanner (Fig. 7A). The expression ofMMP-1 and Fra-1was
also inhibited by treatment with SP600125. On the other hand,
treatment with PD98059 inhibited the phosphorylation of Fra-1
and its upstream activator, ERK1/2, in a dose-dependent manner
(Fig. 7B). However, the phosphorylation of c-Jun was not affected by
treatment with PD98059. MMP-1 expression was also inhibited by
treatment with PD98059 in 143B cells. In the next step, we analyzed
transcription factors binding to the AP-1 element in the MMP-1
promoter by EMSA. Protein complex bound to the AP-1 site was
decreased with nuclear extracts derived from 143B cells treated with
SP600125 or PD98059 in a dose-dependent manner (Fig. 7C). As a
control, no differences in DNA binding to the octamer motif wereFig. 8. SP600125 and PD98059 inhibit MMP-1 release and cell invasion in 143B cells. 143B c
48 h. (A) MMP-1 protein levels in the culture supernatants from 143B cells treated with SP60
ELISA experiments in a period of 48 h (**pb0.01). (B) Viability of cultured cells was determi
period of 48 h. (C) 143B cells were seeded in the type I collagen-coated upper chamber con
chamber contained medium supplemented with 10% FCS. Then cells were incubated for 48
*pb0.05 vs. the invasion of non-treated 143B cells.noted in the absence or presence of SP600125 and PD98059. Further-
more, we analyzed extracellular release of MMP-1 from 143B cells
treated with SP600125 and PD98059. MMP-1 release was inhibited
by treatment with SP600125 and PD98059 in 143B cells (Fig. 8A),
whereas cell viability was not affected by treatment with SP600125
and PD98059 (Fig. 8B). However, treatment with SP600125 and
PD98059 caused a marked decrease in 143B cell invasion thorough
type I collagen (Fig. 8C). These data indicate that phosphorylation of
c-Jun and Fra-1 by upstream activators is required for MMP-1 gene
expression and cell invasion in 143B cells.
We ﬁnally investigated the role of c-Jun and Fra-1 in MMP-1 ex-
pression using siRNA for c-Jun and Fra-1. siRNA for c-Jun and Fra-1
speciﬁcally inhibited the expression of MMP-1 in 143B cells (Fig. 9A).
siRNA for c-Jun also signiﬁcantly down-regulated Fra-1 expression,
while siRNA for Fra-1 slightly reduced the expression of c-Jun. Further-
more, protein complex bound to the AP-1 site was decreased with
nuclear extracts derived from 143B cells transfected with siRNA for
c-Jun and Fra-1 (Fig. 9B).While cell viabilitywas not affected by c-Jun
and Fra-1 knockdown (Fig. 9C), siRNA for c-Jun and Fra-1 caused a
marked decrease in 143B cell invasion thorough type I collagen
(Fig. 9D). These results demonstrate that c-Jun and Fra-1 are essential
for MMP-1 gene expression and cell invasion in 143B cells.
4. Discussion
In this study, we showed that cell invasion is dependent onMMP-1
in 143B cells, a human osteosarcoma cell line that has a high pul-
monary metastatic potential. Accordingly, we posit that MMP-1 plays
a crucial role in the development of pulmonary metastases in osteo-
sarcomas (Fig. 10). Similarly, recent studies showed that MMP-1 is
highly expressed in chondrosarcomas, and small hairpin RNA for
MMP-1 inhibits osteosarcoma pulmonary metastases in vivo [24].ells were treated with SP600125 (0, 2.5, 5 or 10 μM) or PD98059 (0, 2.5, 5 or 10 μM) for
0125 or PD98059 were determined by ELISA. Data are mean±SD of three independent
ned by WST-8 assay. Data are mean±SD of three independent WST-8 experiments in a
taining serum-free medium supplemented with SP600125 or PD98059, and the lower
h. Data are mean±SD of three independent invasion experiments in a period of 48 h.
Fig. 9. c-Jun and Fra-1 regulateMMP-1 expression and cell invasion in 143B cells. (A) 143B
cellswere transfectedwith either c-Jun, Fra-1 or control siRNA and then incubated for 72 h.
Protein levels of MMP-1, c-Jun, Fra-1 and actin at 72 h after transfection were determined
byWestern blot analysis. (B) EMSA with nuclear extracts from 143B cells transfected with
c-Jun, Fra-1 or control siRNAwas performedwith the indicated probes. (C) 143B cells were
transfectedwith either c-Jun, Fra-1or control siRNAand then incubated for 24 h.Thecells at
24 h after transfection were seeded and then incubated for another 48 h. Viability of
cultured cells was determined byWST-8 assay. Data are mean±SD of three independent
WST-8 experiments in a period of 48 h. (D) The 143B cells at 24 h after transfection were
seeded in the type I collagen-coated upper chamber containing serum-free medium, and
the lower chamber contained medium supplemented with 10% FCS. Then, cells were
incubated for another 48 h.Data aremean±SDof three independent invasion experiments
in a period of 48 h. *pb0.05 vs. the invasion of 143B cells transfected with control siRNA.
Fig. 10. Schematic diagram of MMP-1-dependent ost
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tidases [25]. Although there is a wide range of biological functions of
MMPs in cancer, a central role is the degradation and remodeling of the
ECM, paving the way through the peripheral tissue for invasion and
metastasis [26]. Indeed, MMP-9, otherwise known as gelatinase B, is
normally associated with prognosis and metastasis in osteosarcomas
[7,8]. A linkage with prognosis has also been identiﬁed in osteosar-
comas where positive MMP-9 staining was associated with an overall
5-year survival of 28% in comparison to 79% for the MMP-9 negative
group [27]. The importance of MMP-9 in osteosarcoma can be inferred
from the fact that MMP-9 overexpression in rat osteosarcomas was
associated with increased metastatic potential [28]. Our result also
showed that MMP-9 is up-regulated 11.8-fold in 143B cells as com-
pared toMNNGcells (Table 1). Butmore impressively,MMP-1was up-
regulated 134.9 fold in 143B cells and was required for maximal cell
invasion. Thus, our ﬁndings highlight the further importance of MMP-
1 in addition to MMP-9 for metastasis in osteosarcomas.
Expression ofMMP genes is transcriptionally regulated by a variety
of extracellular factors including cytokines, growth factors and cell
contact to ECM [29]. Most members of theMMP family share common
cis-elements in their promoter sequences, which allow a tight control
of cell-speciﬁc expression. Some of the key transcription factor-
binding sites involved in the regulation of MMP genes are: the AP-1
site, the ETS sites, the NF-κB site, the signal transducers and activators
of transcription site, and other regulated cis-elements [30]. Previous
reports showed that theMMP-1 gene is transcriptionally up-regulated
by CCAAT enhancer-binding protein-β in IL-1β-stimulated A549 lung
carcinoma cells [31] and by HER/Neu-activated ETS transcription
factor ER81 in breast tumors [20]. Further, theMMP-1 gene is reported
to be up-regulated by the Ewing's sarcoma associated EWS-ER81 and
EWS-Fli-1 fusion proteins together with c-Jun and p300 [21]. In ad-
dition, Fra-1 in A2058 melanoma cells [32] and PEA3 in esophageal
adenocarcinoma [33] activate MMP-1 expression. These reports col-
lectively demonstrate thatMMP-1 gene expression is transcriptionally
up-regulated by AP-1 and ETS transcription factors. Indeed, our resultseosarcoma invasion and pulmonary metastasis.
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transcription factors, c-Jun and Fra-1, and ETS transcription factor
PEA3 in 143B cells (Figs. 5 and 9).
Interestingly, our results showed that Fra-1 is highly expressed in
143B cells (Fig. 6) and down-regulated by treatment with SP600125,
an inhibitor of JNK1/2 that suppresses c-Jun phosphorylation in 143B
cells (Fig. 7A). siRNA for c-Jun also down-regulated Fra-1 expression
in 143B cells (Fig. 9A). These ﬁndings may be explained by the fact
that c-Jun is bound to a cis-element within the human Fra-1 promoter
and thereby up-regulates Fra-1 gene transcription [34–37] (Fig. 10).
On the other hand, Fra-1 modulates AP-1 dimer composition by pro-
moting the accumulation of c-Jun in response to oncogenic RAS
signaling. c-Jun stabilization requires the phosphorylation of Fra-1 in
response to ERK signaling [38]. Accordingly, we found that down-
regulation of Fra-1 also leads to reduced c-Jun levels, suggesting that
Fra-1 regulates c-Jun stabilization in 143B cells (Fig. 10). Taken
together, published and our results collectively indicate that c-Jun and
Fra-1 synergistically stimulateMMP-1 transcription in osteosarcomas.
Although mutation of the ETS motifs in the MMP-1 promoter had a
minor effect onMMP-1 gene expression compared to mutation of the
AP-1 motif, MAPK signaling is important in the activation of PEA3, an
ETS-domain transcription factor [39]. Therefore, both JNK and ERK
MAPK pathways may also play a role in the PEA3 controlled events in
MMP-1 gene expression. Further studies are needed to elucidate the
regulatory role of the MAPK/PEA3 axis in mediating MMP-1
transcriptional activation in osteosarcoma cells.
Previous studies showed that the CXCR4/SDF-1α axis mediates
hypoxia-induced chondrosarcoma cell invasion through ERK signaling
and increases MMP-1 expression [40]. This axis enhances motility of
human osteosarcoma cells through MAPK/ERK kinase1/2, ERK and
NF-κB-dependent pathways [41]. CXCR4 is associated with prognosis
and metastases in osteosarcoma [7,8]. Indeed, our results suggest that
CXCR4 is highly expressed in 143B cells (Fig. 1A). As the CXCR4/SDF-
1α axis enhances pulmonary metastases in osteosarcoma in a mouse
model [9], our results also suggest that CXCR4 may mediate meta-
stasis of osteosarcomas to the lung in human.
Fig. 10 schematically illustrates MMP-1-dependent osteosarcoma
invasion and pulmonary metastasis. Altogether, our results revealed
that activation of the JNK and ERK pathways play crucial roles in
constitutive activation ofMMP-1 gene transcription in 143B cells. Both
of these MAPK signaling pathways, in concert, activate c-Jun and Fra-1,
eventually leading to the binding of these transcription factors to the
AP-1motif in theMMP-1promoter to initiate the transcriptional activity
of this gene. In conclusion, our data indicate that MMP-1 plays a central
role in osteosarcoma invasion. Therefore, MMP-1might be a biomarker
and a therapeutic target for osteosarcoma invasion and pulmonary
metastasis.References
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